Literature DB >> 10766874

Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms.

Y Kenan1, T Murata, Y Shakur, E Degerman, V C Manganiello.   

Abstract

The N-terminal portion of phosphodiesterase (PDE) 3 was arbitrarily divided into region 1 (amino acids 1-300), which contains a large hydrophobic domain with six predicted transmembrane helices, and region 2 (amino acids 301-500), with a smaller hydrophobic domain ( approximately 50 residues). To analyze these regions, full-length human (H)PDE3A and mouse (M)PDE3B and a series of N-terminal truncated mutants were synthesized in Sf9 cells. Activities of HPDE3A, H3A-Delta189, MPDE3B, and M3B-Delta196, which retained all or part of the hydrophobic domain in region 1, were recovered almost entirely in particulate fractions. H3A-Delta321 and M3B-Delta302, containing region 2, were recovered essentially equally in particulate and cytosolic fractions. H3A-Delta397 and H3A-Delta457, lacking both hydrophobic domains, were predominantly cytosolic. H3A-Delta510 and M3B-Delta604, lacking both regions 1 and 2, were virtually completely cytosolic. M3B-Delta196 eluted as a large aggregated complex during gel filtration. With removal of greater amounts of N-terminal sequence, aggregation of PDE3 decreased, and H3A-Delta607, H3A-Delta721, and M3B-Delta604 eluted as dimers. Truncated HPDE3A proteins were more sensitive than full-length HPDE3A to inhibition by lixazinone. These results suggest that the hydrophobic domains in regions 1 and 2 contain structural determinants important for association of PDE3 with intracellular membranes, as well for self-association or aggregation during gel filtration and sensitivity to a specific inhibitor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766874     DOI: 10.1074/jbc.275.16.12331

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes.

Authors:  Y H Choi; D Ekholm; J Krall; F Ahmad; E Degerman; V C Manganiello; M A Movsesian
Journal:  Biochem J       Date:  2001-01-01       Impact factor: 3.857

Review 2.  From PDE3B to the regulation of energy homeostasis.

Authors:  Eva Degerman; Faiyaz Ahmad; Youn Wook Chung; Emilia Guirguis; Bilal Omar; Lena Stenson; Vincent Manganiello
Journal:  Curr Opin Pharmacol       Date:  2011-10-14       Impact factor: 5.547

Review 3.  Vasopressin and disruption of calcium signalling in polycystic kidney disease.

Authors:  Fouad T Chebib; Caroline R Sussman; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

4.  Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.

Authors:  Xiaoyun Wu; Gavin R Schnitzler; Galen F Gao; Brett Diamond; Andrew R Baker; Bethany Kaplan; Kaylyn Williamson; Lindsay Westlake; Selena Lorrey; Timothy A Lewis; Colin W Garvie; Martin Lange; Sikander Hayat; Henrik Seidel; John Doench; Andrew D Cherniack; Charlotte Kopitz; Matthew Meyerson; Heidi Greulich
Journal:  J Biol Chem       Date:  2020-01-31       Impact factor: 5.157

5.  Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB.

Authors:  Faiyaz Ahmad; Rebecka Lindh; Yan Tang; Marie Weston; Eva Degerman; Vincent C Manganiello
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

6.  Protein kinase B/Akt phosphorylation of PDE3A and its role in mammalian oocyte maturation.

Authors:  Seung Jin Han; Sergio Vaccari; Taku Nedachi; Carsten B Andersen; Kristina S Kovacina; Richard A Roth; Marco Conti
Journal:  EMBO J       Date:  2006-11-23       Impact factor: 11.598

Review 7.  Therapeutic potential of PDE modulation in treating heart disease.

Authors:  Walter Knight; Chen Yan
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

8.  The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s).

Authors:  Moses Xie; Brigitte Blackman; Colleen Scheitrum; Delphine Mika; Elise Blanchard; Tao Lei; Marco Conti; Wito Richter
Journal:  Biochem J       Date:  2014-05-01       Impact factor: 3.857

9.  Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells.

Authors:  Kenichi Hiramoto; Taku Murata; Kasumi Shimizu; Hiroshi Morita; Madoka Inui; Vincent C Manganiello; Toshiro Tagawa; Naoya Arai
Journal:  Cell Signal       Date:  2014-04-03       Impact factor: 4.315

10.  Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation.

Authors:  Jacqueline Arp; Mark G Kirchhof; Miren L Baroja; Steven H Nazarian; Thu A Chau; Craig A Strathdee; Eric H Ball; Joaquín Madrenas
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.